Data leads scientists to declare 2015 Paris agreement to keep global heating below 1.5C ‘dead in the water’ ...
Cuts in sulfur emissions from oceangoing vessels have been tied to a reduction in lightning stroke density along heavily ...
A report published by Lunio, the invalid traffic (IVT) detection & prevention platform, has revealed that $63 billion ...
Neuroscientists have been trying to understand how the brain processes visual information for over a century. The development ...
Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD ...
Dyslexia is a common developmental disorder, affecting around 7% of the global population. It is characterized by ...
A new study shows human immune systems differ across populations, raising new questions for medicine and global drug research ...
Reservoirs are indispensable for hydropower, irrigation, and flood control, but their storage fluctuations often escape ...
News Medical on MSN
First-in-human drug trial lowers high blood fats
In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug ...
A selective Liver X Receptor inverse agonist lowered triglycerides and post-meal cholesterol in people, opening a safer path to treat hypertriglyceridemia.
Researchers developed TLC-2716, a liver- and gut-targeted drug that selectively reduced LXR activity, lowering triglycerides, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback